26th March 2019 – Can-Fite BioPharma
Limited issued an announcement, which is summarized as follows:
The phase II
advanced liver cancer study of CF-102 (Namodenoson) did not achieve its primary end
point of median overall survival in the whole population of 78 patients,
however, superiority in median overall survival was found in the largest study
subpopulation of 56 patients and in secondary end points including objective
response in the whole population, strongly supporting the progression into
Phase III.
Dr. Josep
Llovet, a Key Opinion Leader in the field of liver cancer, said: “Considering
that patients with advanced HCC and severe liver dysfunction do not have any
accepted standard of care, the current data from this Phase II trial suggest a
signal of efficacy that supports continuing the development of Namodenoson with
a Phase III study in this population.”
Dr. Salomon
Stemmer, the Israeli principal investigator, added: “Given the evidence of
clinical benefit of Namodenoson, I plan on offering it to selected HCC CPB
patients with the drug in the compassionate use setting.”
The original
website link：